Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Agitation
Alzheimer's Disease

Interventions

DRUG: AVP-923-20
DRUG: Placebo
DRUG: AVP-923-30

Sponsor

Avanir Pharmaceuticals